Evaxion Biotech A/S

Evaxion Biotech is a clinical-stage AI-immunologyTM platform company that simulates the human immune system and generates predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Evaxion Biotech is now in clinical trials for the treatment of various cancers with two lead product candidates, EVX-01 and EVX-02. Evaxion Biotech has three patented AI platforms: PIONEER for immuno-oncology, EDEN for bacterial disease, and RAVEN for viral disease.

Even while modern medicine is quickly developing, far too many people are still dying from cancer, drug-resistant germs, and other infectious diseases. The demand for innovative, effective drugs has never been greater, and it will only increase. Every day, advances in artificial intelligence (AI) technology move us closer to a future in which a wide range of essential diseases can be treated in a focused, patient-specific manner. According to Evaxion Biotech, there is a huge market for novel, efficient, and tailored pharmaceuticals, as well as a significant means to improve patients' quality of life. This is why their goal is to save lives using AI-powered immunotherapies.

AI-powered immunotherapies are at the center of Evaxion's work to transform medication development and, eventually, save patients' lives. They connect artificial intelligence, bioinformatics, and medication research to provide breakthrough immunotherapies to patients. They employed AI to create a diverse pipeline of candidate immunotherapies that target two of the world's most pressing unmet medical needs: cancer and infectious diseases.

Founded: 2008

Headquarters: Hørsholm, Capital Region

Website: https://www.evaxion-biotech.com